Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

Launched by FOX CHASE CANCER CENTER · Sep 19, 2017

Keywords

ClinConnect Summary

This clinical trial is studying patients with renal cell carcinoma (a type of kidney cancer) and urothelial carcinoma (cancer that affects the urinary system, including the bladder). Researchers want to understand why some patients develop new tumors after receiving a specific type of treatment called immune checkpoint blockade (ICB), which helps the body’s immune system fight cancer. They will look at tumor samples taken before and after treatment to see how the cancer changed and whether the new tumors are related to resistance to the treatment.

To participate in this trial, patients should have had surgery for their cancer and received ICB treatment that initially helped, but then developed new lesions that were also surgically removed. There will also be a group of patients who had surgery for their cancer but did not receive ICB treatment, to compare the results. Participants can expect their tumor samples to be analyzed for changes that may have contributed to the cancer spreading. This study aims to provide valuable insights that could improve future cancer treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Eligible patients will include retrospectively identified patients with RCC or UC who have received treatment with ICB and achieved clinical benefit but subsequently developed a solitary new/progressive lesion that was removed surgically. Patients with other tumor types who otherwise meet criteria may be included at a later time
• • Additionally, a group of patients with RCC who have undergone a metastasectomy but who did not receive treatment with ICB will be identified. These patients may be approached for study participation to serve as a comparator group
• Exclusion Criteria:
• • -